{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:57:51Z","timestamp":1790798271587,"version":"4.1.0"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2012,11,13]],"date-time":"2012-11-13T00:00:00Z","timestamp":1352764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0049006","type":"journal-article","created":{"date-parts":[[2012,11,13]],"date-time":"2012-11-13T22:21:09Z","timestamp":1352845269000},"page":"e49006","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":195,"title":["Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy"],"prefix":"10.1371","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct00794664","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Mary P.","family":"McGowan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Tardif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Ceska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley J.","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Handrean","family":"Soran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Gouni-Berthold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Wagener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Chasan-Taber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,11,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jacl.2011.03.452","article-title":"Familial hypercholesterolemias: Prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert panel on Familial Hypercholesterolemia","volume":"5","author":"Hypercholesterolemia National Lipid Association Expert panel on Familial","year":"2011","journal-title":"J Clin Lipidol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2003.11.010","article-title":"Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia","volume":"173(1)","author":"F Civeira","year":"2004","journal-title":"Atherosclerosis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1161\/ATVBAHA.107.145151","article-title":"A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia","volume":"27(8)","author":"HJ Avis","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1161\/CIRCULATIONAHA.106.671016","article-title":"Statin treatment in children with familial hypercholesterolemia: the younger, the better","volume":"116(6)","author":"J Rodenburg","year":"2007","journal-title":"Circulation"},{"key":"ref5","first-page":"49","article-title":"Familial hypercholesterolaemia","volume":"25(1)","author":"AD Marais","year":"2004","journal-title":"Clin Biochem Rev"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1527-3466.2002.tb00097.x","article-title":"LDL Apheresis: an effective and safe treatment for refractory hypercholesterolemia","volume":"20(4)","author":"LC Hudgins","year":"2002","journal-title":"Cardiovasc Drug Rev"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Moriarty PM, Gibson CA, Flechsenhar K (2007) Familial hypercholesterolemia and lipid apheresis. In: Davidson MH, Toth PP, Maki KC, eds. Contemporary Cardiology: Therapeutic Lipidology. Totowa, NJ: Humana Press; 267\u2013289p.","DOI":"10.1007\/978-1-59745-533-6_13"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375(9719)","author":"FJ Raal","year":"2010","journal-title":"Lancet"},{"key":"ref9","unstructured":"Stein EA, Dufour R, Gagne C, Gaudet D, East C, <etal>et al<\/etal>.. (2010) Abstract: 5036 A randomized, double-blind, placebo-controlled study to assess efficacy and safety of mipomersen as add-on therapy in heterozygous familial hypercholesterolemia patients with coronary artery disease. Eur Heart J 31(Abstract Suppl): 898."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1517\/14712598.7.7.1021","article-title":"The versatility of oligonucleotides as potential therapeutics","volume":"7(7)","author":"F Eckstein","year":"2007","journal-title":"Expert Opin Biol Ther"},{"key":"ref11","first-page":"3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation","volume":"106(25)","year":"2002"},{"key":"ref12","unstructured":"National Institute for Health and Clinical Excellence. (2008) Identification and management of familial hypercholesterolaemia. NICE clinical guideline 71. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.nice.org.uk\" xlink:type=\"simple\">http:\/\/www.nice.org.uk<\/ext-link>. Accessed 2012 Mar 20."},{"key":"ref13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.atherosclerosis.2008.02.009","article-title":"Recommendations for the use of LDL Apheresis","volume":"198","author":"GR Thompson","year":"2008","journal-title":"Atherosclerosis"},{"key":"ref14","first-page":"2375","article-title":"European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG). European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts)","volume":"28(19)","author":"I Graham","year":"2007","journal-title":"Eur Heart J"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1148\/radiol.2511080666","article-title":"Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5T","volume":"251(1)","author":"T Yokoo","year":"2009","journal-title":"Radiology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/clinchem\/39.5.773","article-title":"International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material","volume":"39(5)","author":"SM Marcovina","year":"1993","journal-title":"Clin Chem"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/clinchem\/40.4.586","article-title":"International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of international reference material","volume":"40(4)","author":"SM Marcovina","year":"1994","journal-title":"Clin Chem"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"European Atherosclerosis Society Consensus Panel. European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31(23)","author":"BG Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.atherosclerosis.2006.11.037","article-title":"Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)","volume":"192(2)","author":"JM McKenney","year":"2007","journal-title":"Atherosclerosis"},{"key":"ref20","first-page":"1670","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376(9753)","year":"2010","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1365-2265.2008.03490.x","article-title":"Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence","volume":"70(6)","author":"D Preiss","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.clinthera.2007.05.012","article-title":"Cholesterol reduction yields clinical benefits: meta-analysis including recent trials","volume":"29(5)","author":"AL Gould","year":"2007","journal-title":"Clin Ther"},{"key":"ref23","first-page":"1267","article-title":"Cholesterol Treatment Trialists&apos; (CTT) Collaborators. Cholesterol Treatment Trialists\u2019 (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: a prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366(9493)","author":"C Baigent","year":"2005","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2009.11.069","article-title":"Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy","volume":"55(15)","author":"F Akdim","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.amjcard.2010.01.003","article-title":"Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia","volume":"105(10)","author":"F Akdim","year":"2010","journal-title":"Am J Cardiol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1517\/17425250902877680","article-title":"Antisense oligonucleotide pharmacokinetics and metabolism","volume":"5(4)","author":"RS Geary","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref27","first-page":"941","article-title":"Longevity syndromes: Familial hypobeta and familial hyperalpha lipoproteinemia","volume":"88(6)","author":"CJ Glueck","year":"1976","journal-title":"J Lab Clin Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/01.ATV.0000176191.64314.07","article-title":"Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia","volume":"25(9)","author":"RR Sankatsing","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cld.2007.06.010","article-title":"Lipid-lowering agents that cause drug-induced hepatotoxicity","volume":"11(3)","author":"SS Bhardwaj","year":"2007","journal-title":"Clin Liver Dis"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1093\/eurheartj\/ehr148","article-title":"Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia","volume":"32(21)","author":"F Akdim","year":"2011","journal-title":"Eur Heart J"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/eurheartj\/ehs023","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial","volume":"33(9)","author":"ME Visser","year":"2012","journal-title":"Eur Heart J"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0049006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T10:33:10Z","timestamp":1714559590000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0049006"}},"subtitle":[],"editor":[{"given":"Michael","family":"Lipinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,11,13]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2012,11,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0049006","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,13]]}}}